Accreditation Information

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing (ANCC)

This activity is designated for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Upon completion of a CNE request form, statements of credit for nurses will be issued within 30 business days.

ONCC/ILNA Certification Information

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. OCN®, AOCNP®, and AOCNS® nurses may apply 1.0 point in Coordination of Care, Disease-Related Biology, Health Promotion/Screening and Early Detection, Navigation,Oncologic Emergencies,Professional Practice,Psychosocial, Scientific Basis for Practice, Symptom Management, and Treatment categories.

Disclaimer: ONCC review is only for designating content to be used for ILNA points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.


  • Review the molecular pathology of advanced non-small cell lung cancer (NSCLC) and identify clinically relevant mutations that impact treatment selection.
  • Examine strategies oncology nurses can employ to help coordinate care in the community setting to improve adherence to guideline recommendations for molecular testing in NSCLC and discuss the utility of newer technologies, such as next generation sequencing and ctDNA liquid biopsy, in clinical practice.
  • Evaluate targeted treatment options for EGFRm NSCLC, focusing on differences in safety and efficacy profiles of EGFR tyrosine kinase inhibitors (TKIs) and appropriate selection of EGFR-TKI therapy in the first-line setting.
  • Identify current barriers to targeted therapy in the management of advanced NSCLC and discuss strategies nurses can employ to optimize therapy, anticipate and manage toxicities, improve quality of life and patient adherence to oral chemotherapies.
  • Effectively educate NSCLC patients and caregivers on disease diagnosis, testing, and treatment recommendations to enable patients to actively participate in shared decision-making regarding treatment selection and care.

Target Audience

This activity is designed to meet the educational needs of oncology nurses and nurse practitioners attending local ONS Chapter Meetings across the U.S.

Faculty Disclosure

Planner and Faculty Disclosures

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Susan H. Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.


Mary Ellen Hand, RN, BSN–has disclosed that she is a consultant for AstraZeneca

Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP–has no relevant financial relationships to disclose in relation to the content of this activity.

Suzanne Walker, CRNP, MSN, AOCN, BC–has no relevant financial relationships to disclose in relation to the content of this activity.

Elizabeth S. Waxman, RN, MSN, NP-C, AOCN–has no relevant financial relationships to disclose in relation to the content of this activity.

Peer Reviewer:

To come